Hong Kong / HKEX Continues Biotech Momentum in Q3 2021
Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a large extent by new biotech listings.…
GeneHarbor focuses on the development and manufacture of innovative biotech products, enzymes in particular, and enzymatic production of various highly value-added products. The company has developed a proprietary platform technology for production of various enzymes. The technology aims to reduce the cost & increase the life span of the enzymes. The Company also operates its own manufacturing facilities that industrially manufactures biochemicals of the highest standard.
Contact
Unit 507, 5/F, Bio-Informatics Centre, No. 2 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, Hong Kong
Tel: +852 2838 0306
Website: http://www.geneharbortech.com.hk/index.htm
Email: info@geneharbor.com.hk
Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a large extent by new biotech listings.…
Three years after the Hong Kong Stock Exchange (HKEX) introduced reforms to allow and support the listing of pre-profit biotech companies, it has become Asia’s largest, and the world’s second-largest,…
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar 2020 for the Exchange and…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain…
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies…
Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong…
Dr Albert Yu, chairman of the Hong Kong Biotechnology Organization (HKBIO) gives his expert insights into the crucial importance of diagnostics in countering the COVID-19 pandemic, how Hong Kong’s positioning…
Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative…
Dr Desmond Hau, CEO of Pangenia Inc, sits down with PharmaBoardroom to shed light on the company’s progress since taking the reins three years ago. Hau also explains Pangenia’s strategy…
Kelvin Chiu and Isabelle Dutry of Sanwa BioTech in Hong Kong highlight the critical importance of personalised fast-track diagnostics in countering the COVID-19 pandemic, the role that Asian firms have…
Michael Chan, Senior Vice President of Global Issuer Services for the Hong Kong Exchange (HKEX) highlights the vibrancy and diversity that biotechs have brought to the market, HKEX’s three unique…
2019 was a bumper year for biotech companies listing on the Hong Kong Exchange (HKEx), with nine pre-revenue biotechs and eight revenue-generating biotech and biotech-related firms, mostly originating from mainland…
See our Cookie Privacy Policy Here